About Us About Us

Management Team

The drug development process is complex. Our management team offers deep expertise in all aspects of the process to drive products toward commercialization.


Mark R. Baker

Chief Executive Officer

Mr. Baker joined the Company in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President – Corporate, in 2009 became President, and has been CEO since March 2011. From 2003 to 2005, Mr. Baker was Chief Business Officer, Secretary and a director of New York Trans Harbor LLC, a privately-held ferry operation in New York City. From 1997 to 2001, he was Executive Vice President, Chief Legal Officer and Secretary of Continental Grain Company, a privately-held international agri-business and financial concern. Prior thereto, he was a partner and Co-Chairman of the Capital Markets Group of the New York law firm Dewey Ballantine. Mr. Baker has an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.


Pat Fabbio

Senior Vice President and Chief Financial Officer

Pat Fabbio joined the Company in November 2015 as Senior Vice President and Chief Financial Officer. Prior to joining Progenics, Pat was CFO of electroCore and VP Finance for NPS Pharmaceuticals, Inc., a publicly-traded, global rare disease company. Pat has more than 20 years of financial leadership experience in both public and private life science and pharmaceutical companies including; VP Finance, Catalent Pharma Solutions, CFO of Ikano Therapeutics, and senior corporate finance, commercial and transactional roles at Sanofi as well as Corporate Controller for Biomatrix Inc. a publicly-traded biotechnology company that was acquired by Genzyme. Pat graduated from Pace University with a BBA in Accounting and from the Stern School of Business at New York University, with a Master’s Degree in Finance. He has received his certified public accountant license in New Jersey.


Vivien Wong Ph.D.

Executive Vice President, Development

Dr. Wong has been Executive Vice President of Development since 2015. Prior to that date, she served as Senior Vice President of Operations and Portfolio Management and Vice President of Product Development. For three years before joining Progenics in 2007, Dr. Wong was Principal at Theritas Pharmaceutical Consultants. From 1989 to 2004, she held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. Dr. Wong has been a co-author on over 30 scientific articles for peer-reviewed journals. She received a B.Sc. in biology from the Mississippi University for Women, a Ph.D. in anatomy and neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in neurology at the Albert Einstein College of Medicine.

Jessica Jensen

Jessica Jensen, MPH

Vice President, Clinical Development

Jessica Jensen joined Progenics in 2014 and is currently Vice President of Clinical Development. From 2014 to 2016, she held positions of increasing responsibility in the Company across clinical operations, program management, and clinical development. She is a multi-disciplined and dynamic leader, with over 10 years of oncology experience across all phases of clinical research. Prior to joining Progenics, Jessica advanced immunotherapy programs at the Ludwig Institute for Cancer Research where she led global clinical trials of combination therapies with immune checkpoint inhibitors and cancer vaccines. Prior thereto, Jessica led clinical operations activities for an orphan drug program at Gentium SpA, a biopharmaceutical company since acquired by Jazz Pharmaceuticals, and she supported client programs as well as the development of a contract research organization business unit at US Oncology. Jessica began her career in Statistical Programming and Biostatistics after receiving a Master of Public Health degree in Epidemiology & Biostatistics from the George Washington University.

Thomas Strack

Thomas Strack

Vice President, Clinical Affairs

Dr. Strack joined the company as VP Clinical Affairs in Sep 2015. He has more than 20 years of experience in developing novel pharmaceutical products in various therapeutic areas including metabolic/endocrine, oncology and CNS, and held various leadership positions at Eli Lilly & Company (regulatory oncology lead), Pfizer Inc. (Group lead endocrine/metabolic/ophthalmology), Takeda Global Research and Development (Head metabolic clinical development), and Asubio Pharmaceuticals (Head R/D). Dr. Strack received his MD and doctorate degrees from Johannes Gutenberg University, Germany, and is board-certified in internal medicine and endocrinology.

Bryce Tenbarge

Bryce Tenbarge

Vice President, Commercial

Bryce Tenbarge joined Progenics in August 2016 as Vice President, Commercial. Bryce has more than 15 years of commercial leadership experience with highly specialized products including; Vice President of Marketing and Commercialization at Celldex Therapeutics, Senior Director of Global Oncology Marketing at Teva Pharmaceuticals and a variety of roles of increasing responsibility at Bristol-Myers Squibb in professional and payer marketing, market research and business intelligence. Bryce started his career as a commodity trader at Archer Daniels Midland in Chicago prior to receiving his MBA from The Ross School of Business at the University of Michigan.